Ocular Therapeutix's Manufacturing Inspection: Items Of Concern Are 'Addressable,' Shouldn't Delay Product Launch

Ocular Therapeutix Inc (NASDAQ: OCUL) shares sunk nearly 16 percent following a first-quarter earnings miss Friday. Latest Ratings for OCUL DateFirmActionFromTo May 2017BTIG ResearchDowngradesBuyNeutral Feb 2017Cantor...

Continue reading at Benzinga →